Compare Corning Incorporated (GLW) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Moderna, Inc. — how do they compare? Corning Incorporated trades at $157.07 (market cap $150.10B), while Moderna, Inc. trades at $64.31 (market cap $27.09B). The key difference: Corning Incorporated is far larger — about 5.5× Moderna, Inc.'s market cap, and Corning Incorporated pays a 0.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GLW | MRNA | |
|---|---|---|
Market Cap | $150.10B | $27.09B |
Sector | Technology | Health |
52-Week High | $255.79 | $81.80 |
52-Week Low | $52.97 | $22.36 |
Enterprise Value | $158.27B | $23.19B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $187.68, up 2.36% today, with a neutral technical signal and bearish moving averages. Recent earnings beats and strong 2025 results, including $15.63B revenue and $1.60B net income, highlight fundamental strength. The stock has retreated from its June 2026 peak of $271.38, with analyst consensus pointing to a $210.10 price target. Key support lies at $185, with resistance at $191.
The outlook remains positive due to AI-driven optical communication demand and partnerships with NVIDIA and Amazon. Risks include market volatility and competitive pressures, but institutional sentiment is bullish with 54% buy ratings. Upside potential exists if the company maintains its earnings momentum and capitalizes on infrastructure spending trends.
Moderna (MRNA) trades at $67.44, showing modest daily gains amid a bullish technical signal. The company continues to beat earnings expectations despite reporting significant net losses, with revenue declining from pandemic peaks to $1.92B in 2025. Recent positive developments include EU RSV vaccine contracts, Phase 1 cancer trial initiation, and FDA advisory panel support for its mRNA flu vaccine, driving recent stock momentum.
While Moderna's pipeline expansion beyond COVID-19 shows promise with oncology and rare disease applications, substantial financial risks persist with negative profit margins and cash burn. Analyst consensus remains cautious with a $49 price target below current levels, reflecting concerns about revenue sustainability versus pipeline execution risks and valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
